Artisanal bread sold at Kroger, Walmart voluntarily recalled
Out of an abundance of caution, the company, headquartered in West Hartford, Connecticut, issued a recall for its 'Lewis Bake Shop Artisan Style 1/2 Loaf' on July 10, according to the FDA. The company warns that "people with a nut allergy or severe sensitivity to hazelnuts run the risk of serious or life-threatening allergic reactions" if they consume the bread.
Hartford Bakery said it had removed all products linked to the six affected production lots. The recalled bread was distributed in Alabama, Arkansas, Georgia, Illinois, Indiana, Kentucky, Michigan, Mississippi, Missouri, Ohio, Tennessee and Wisconsin retailers, including Kroger and Walmart, according to the FDA.
The FDA said there had been no major reports of injury or illness related to the recalled bread.
"Hartford Bakery is aware of one customer who experienced digestive discomfort after consumption," the recall reads. "Hartford Bakery also received consumer complaints from those who saw the nuts before consuming the product."
What does the recalled artisanal bread look like?
The recalled bread comes in a flexible plastic bag marked with the following information:
How was the undeclared allergen found?
Hartford Bakery initiated the recall after finding that about 883 loaves of bread from six production lots contained visible hazelnuts and were distributed in 'Lewis Bake Shop Artisan Style 1/2 Loaf' packaging.
Although the packaging reads "May Contain Tree Nuts," it does not say that it "Contains Hazelnuts." An investigation by the company revealed that an error in packaging led to the allergen being undeclared.
Jonathan Limehouse covers breaking and trending news for USA TODAY. Reach him at JLimehouse@gannett.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
an hour ago
- San Francisco Chronicle
Ousted FDA vaccine chief Vinay Prasad is returning to the agency
In this undated photo provided by the U.S. Food and Drug Administration, Vinay Prasad smiles for a portrait. (U.S. FDA via AP) AP WASHINGTON (AP) — A Food and Drug Administration official is getting his job back as the agency's top vaccine regulator, less than two weeks after he was pressured to step down at the urging of biotech executives, patient groups and conservative allies of President Donald Trump. Dr. Vinay Prasad is resuming leadership of the FDA center that regulates vaccines and biotech therapies, a spokesperson for the Department of Health and Human Services said in a statement Monday. End-of-Summer Sale! 25¢ for 3 months. Save on access. End-of-Summer Sale! 25¢ for 3 months. Save on access. ACT NOW Prasad left the agency late last month after drawing ire of right-wing activists, including Laura Loomer, because of his past statements criticizing Trump. Advertisement Article continues below this ad A longtime a critic of FDA's standards for approving medicines, Prasad briefly ordered the maker of a gene therapy for Duchenne's muscular dystrophy to halt shipments after two patient deaths. But that action triggered pushback from the families of boys with the fatal condition and libertarian supporters of increased access to experimental medicines. Prasad's decision to pause the therapy was criticized by The Wall Street Journal editorial board, former Republican Sen. Rick Santorum and others. The FDA swiftly reversed its decision suspending the therapy's use. Loomer posted online that Prasad was 'a progressive leftist saboteur,' noting his history of praising liberal independent Sen. Bernie Sanders. But Prasad has had the backing of FDA Commissioner Marty Makary and health secretary Robert F. Kennedy Jr., who have both called for scrutinizing the use of COVID-19 vaccines. Under Prasad, the FDA restricted the approval of two new COVID-19 shots from vaccine makers Novavax and Moderna and set stricter testing requirements for future approvals. Advertisement Article continues below this ad ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Gizmodo
an hour ago
- Gizmodo
FDA Rehires Controversial Biologics Chief Just Days After Trump Fired Him
The circus was performing at the Food and Drug Administration this weekend, apparently. The FDA has hired Vinay Prasad to oversee the Center for Biologics Evaluation and Research—less than two weeks after he left that same role. Endpoints News was the first to report on Prasad's rehiring on Saturday. He was initially reportedly fired by President Donald Trump himself, following growing pressure from Laura Loomer and other conservative voices who criticized him over the agency's regulation of a gene therapy developed by Sarepta Therapeutics. 'At the FDA's request, Dr. Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research,' Andrew Nixon, communications officer for the Department of Health and Human Services, told Gizmodo. Prasad is a hematologist-oncologist and epidemiologist formerly based at the University of California-San Francisco. He has also regularly written editorials, articles, and studies critical of the medical establishment and public health agencies like the FDA. While some of his critiques have enjoyed support from many in the public health field, such as calling for a stricter standard when approving new therapies, others have been more controversial. The often-combative Prasad has criticized the government's initial response to covid-19 as too restrictive, argued that many people didn't need the covid-19 vaccine, including children, and downplayed the health impacts of long covid, to name a few examples. FDA Commissioner Marty Makary first hired Prasad to head CBER in early May. He was also additionally named the FDA's chief medical and scientific officer. But it didn't take long for Prasad to collect more enemies. Under his reign, the FDA butted heads with Sarepta Therapeutics over its Elevidys gene therapy treatment for the rare and life-shortening condition Duchenne muscular dystrophy (DMD). Following the deaths of three patients linked to the drug, the FDA ordered Sarepta in mid-July to pause all shipments of the therapy until further notice. But 10 days later, the agency reversed course and recommended the drug to patients capable of walking. Days after that, Prasad left the FDA. Though the FDA stated officially that Prasad left of his own volition to 'spend more time with his family,' Politico soon reported that Trump had pushed for Prasad's firing over the objections of Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Makary. Prior to Trump's intervention, several right-wing influencers—most notably Laura Loomer—called for Prasad's head over his management of the Sarepta situation. Loomer and others also maligned Prasad as a 'progressive marxist' and saboteur to Trump and the 'Make America Healthy Again' agenda, pointing out that he had once insulted Trump. Prasad's return isn't entirely surprising, though. Days after he left, FDA Commissioner Makary stated that he was working to bring back Prasad. At the time, Makary also called the reports of Trump firing him false, and HHS seems to now be sticking to a similar script. 'Neither the White House nor HHS will allow the fake news media to distract from the critical work the FDA is carrying out under the Trump administration,' Nixon said. Whatever the exact chain of events, Prasad's comeback may signal that Loomer's influence over the White House isn't quite as ironclad as it's appeared. Or maybe it's just another sign that no one there really has any clue what is happening at any given time.
Newsweek
an hour ago
- Newsweek
Nationwide Deodorant Recall Update as FDA Sets Risk Level
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A major recall of popular deodorants sold nationwide has been issued the second-highest risk classification by the U.S. Food and Drug Administration (FDA). The recall of three Power Stick deodorants, affecting more than 67,000 products sold across the United States, was voluntary issued by Pennsylvania-based maker A.P. Deauville on July 10. FDA inspectors classified the recall a Class II on July 31. The deodorants sold at retailers, including Dollar Tree and Amazon, include: Power Stick for Her Roll-On Antiperspirant Deodorant (Powder Fresh), Power Stick Invisible Protection Roll-On Antiperspirant Deodorant (Spring Fresh), and Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant (Original). Newsweek contacted the company for comment on July 17. Why It Matters The recall signaled that the recalled Power Stick products were linked to violations of Current Good Manufacturing Practice (CGMP) requirements, which are intended to ensure drug products are produced under quality systems that assure identity, strength, quality and purity. A recall is designated Class II status, the second highest of three, in situations where use "may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote," the FDA says. A.P. Deauville is also a manufacturer of shampoos, conditioners, lotion, body washes and facial wipes. In 2005, the company's Power Stick product also had a $50,000 settlement with the California Air Resources Board based on accusations that products contained volatile organic compounds beyond the state limit. What To Know The recall covered the three antiperspirants with the following lot numbers: Power Stick for Her Roll-On Antiperspirant Deodorant Powder Fresh, 1.8 oz/ 53 mL UPC Code 815195019313—(21,265 cases) Power Stick Invisible Protection Roll-On Antiperspirant Deodorant Spring Fresh, 1.8 oz/53 mL UPC Code 815195018194—(22,482 Cases) Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant, 1.8 oz/53 mL UPC Code 815195018224—(23,467 Cases) Consumers are urged to top using the products and follow retailer or manufacturer guidance for returns or disposal. The FDA identified "CGMP deviations" as the reason for the recall but did not specify which regulations were not met. What People Are Saying Manufacturer A.P. Deauville, per its website: "Our antiperspirant/deo sticks and shower products are manufactured in our FDA regulated factory. We could save money 'outsourcing' or not caring enough to make it ourselves, but we CHOOSE to own our factory and make our product. With those savings, we can have the best quality and ensure you can afford our great products." What Happens Next? The FDA's enforcement report listed the recalls as ongoing.
